StockNews.AI
ALGS
StockNews.AI
20 hrs

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

1. Aligos to present six studies at the International HBV Meeting. 2. Data shows ALG-000184 reduces HBV cccDNA in preclinical trials. 3. New ASO strategy targeting HDV offers potential cure. 4. Progress reported in Phase 2 B-Supreme study for chronic HBV. 5. ALGS strengthens commitment to innovation in liver disease therapies.

9m saved
Insight
Article

FAQ

Why Bullish?

Positive data on ALG-000184 and new strategies signal potential market advantages. Historically, favorable presentations have boosted biotech stock prices.

How important is it?

The article highlights significant advancements and studies, directly affecting investor views on ALGS.

Why Short Term?

Presentations at the HBV Meeting are expected to influence investors' immediate perceptions and stock performance.

Related Companies

GILDBMYVRTX
September 03, 2025 16:05 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced six presentations, including three oral presentations, at the 2025 International HBV Meeting, being held September 8 – 12, 2025 in Berlin, Germany. The company and its collaborators’ commitment to advancing next-generation therapies for liver and viral diseases is reflected in these presentations, with topics spanning novel approaches, molecular strategies, insights into the mechanisms of action of ALG-000184, as well as a new strategy to potentially cure hepatitis delta virus (HDV) infection utilizing a proprietary antisense oligonucleotide (ASO) approach. “We are pleased to present six preclinical presentations at the International HBV Meeting, that showcase our continued innovation in liver and viral diseases. With the Phase 2 B-Supreme study progressing nicely, we are pleased to present, for the first time, the direct effects of ALG-000184 in reducing HBV cccDNA in a preclinical setting. These data help corroborate the clinical observations of HBV antigen reductions seen in patients with chronic HBV infection treated with ALG-000184 monotherapy to date and are a direct indication that ALG-000184 can invoke the secondary mechanism of CAM-Es,” stated Lawrence Blatt, PhD, MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “While we remain committed to the continued development of our best/first-in-class CAM-E ALG-000184 for chronic HBV infection, we are pleased to broaden our pipeline with the presentation of our discovery stage ASO program for the treatment of HDV. HDV coinfection with HBV leads to more rapid disease progression and our ASO uniquely targets the destruction of the viral genome, making this mechanism uniquely suited towards a potential HDV cure. Ongoing work will be aimed at selection of the HDV-targeted ASO clinical development candidate.” Details on the presentations are as follows: Paper #: 52Type: Oral PresentationTitle: The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experimentsPresenter: Yannick Debing, PhDDate/Time: September 11, 2025 at 10:30am – 12:00pm CETSession: Session X: Therapy II Paper #: 53Type: Oral PresentationTitle: Antisense oligonucleotide-based strategy to target hepatitis delta virus infectionsPresenter: Julie Lucifora, PhD, CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de LyonDate/Time: September 11, 2025 at 10:30am – 12:00pm CETSession: Session X: Therapy II Paper #: 2Type: Oral PresentationTitle: A Syrian hamster model of persistent HDV infectionPresenter: Elias Broeckhoven, KU Leuven, Department of Microbiology, Immunology & Transplantation, Rega Institute; Virology, Antiviral Drug and Vaccine Research Group; Laboratory of Molecular Vaccinology & Vaccine Discovery (MVVD)Date/Time: September 8, 2025 at 5:00pm – 6:30pm CETSession: Molecular Virology I Paper #: 283Type: Poster PresentationTitle: Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitroPresenter: Hannah VanrusseltDate/Time: September 10, 2025 at 11:00am – 12:00pm CETSession: Poster Session II Paper #: 285Type: Poster PresentationTitle: Capsid assembly modulators bind and directly target HBeAgPresenter: Jordi VerheyenDate/Time: September 10, 2025 at 11:00am – 12:00pm CETSession: Poster Session II Paper #: 127Type: Poster PresentationTitle: PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cellsPresenter: Vaclav Janovec, PhD, University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Department of Genetics and Microbiology, Faculty of Science, Charles University, BIOCEV, Institute of Organic Chemistry and Biochemistry of the Czech Academy of SciencesDate/Time: September 8, 2025 at 5:00pm – 6:30pm CETSession: Molecular Virology The presentations can be found on the Posters & Presentations section of the Aligos website (www.aligos.com) after the live event. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses. For more information, please visit www.aligos.com or follow us on LinkedIn or X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ financial results and performance as well as research and development activities, including regulatory status and the timing of announcements and updates relating to our regulatory filings and clinical trials. Such forward looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance, or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, and other matters that could affect the sufficiency of Aligos’ capital resources to fund operations. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.   Investor ContactAligos Therapeutics, Inc.Jordyn TaraziVice President, Investor Relations & Corporate Communications+1 (650) 910-0427jtarazi@aligos.com Media ContactInizio EvokeJake RobisonVice PresidentJake.Robison@inizioevoke.com

Related News